Vanda Pharmaceuticals Financials - Benzinga

Vanda Pharmaceuticals Inc

VNDANASDAQ

Trade with Public

Trade with Public

$5.13

0.020.39%

At close: Sep 18, 5:00 PM EST

$5.03

-0.1-1.95%

After Hours: 6:35 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Vanda Pharmaceuticals Financials

Vanda Pharmaceuticals (VNDA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate

Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of $(0.46) per share from

Benzinga Newsdesk

PRO
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est

Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Vanda Pharmaceuticals Raises FY2026 Sales Guidance from $230.000M-$260.000M to $240.000M-$290.000M vs $257.202M Est

Benzinga Newsdesk

PRO
Vanda Pharma Q1 EPS $(0.82) Misses $(0.69) Estimate, Sales $51.718M Miss $54.978M Estimate

Benzinga Newsdesk

PRO
Vanda Pharmaceuticals Sees FY2026 Sales $230.000M-$260.000M vs $271.275M Est

Vanda Pharmaceuticals (NASDAQ:VNDA) sees FY2026 sales of $230.000 million-$260.000 million vs $271.275 million analyst estimate.

Benzinga Newsdesk